<DOC>
	<DOCNO>NCT02097810</DOCNO>
	<brief_summary>Entrectinib ( RXDX-101 ) orally available inhibitor tyrosine kinases TrkA ( cod gene NTRK1 ) , TrkB ( cod gene NTRK2 ) , TrkC ( cod gene NTRK3 ) , ROS1 ( cod gene ROS1 ) , ALK ( cod gene ALK ) . Molecular alteration one target present several different tumor type , include non-small cell lung cancer ( NSCLC ) , colorectal cancer ( CRC ) , prostate cancer , papillary thyroid cancer , pancreatic cancer , neuroblastoma . Patients locally advanced metastatic cancer detectable molecular alteration target interest may eligible enrollment . Phase 1 assess safety tolerability entrectinib via standard dose escalation scheme determine recommend Phase 2 dose . Safety efficacy assess dose expansion portion study .</brief_summary>
	<brief_title>Study Oral RXDX-101 Adult Patients With Locally Advanced Metastatic Cancer Targeting NTRK1 , NTRK2 , NTRK3 , ROS1 , ALK Molecular Alterations .</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Key Histologically cytologically confirm diagnosis locally advance metastatic solid tumor NTRK1 , NTRK2 , NTRK3 , ROS1 , ALK molecular alteration . Measurable disease accord RECIST version 1.1 . Prior cancer therapy allow , include crizotinib , ceritinib , investigational drug . Prior radiotherapy allow Patients control asymptomatic central nervous system involvement allow . Resolution acute toxic effect ( exclude alopecia ) prior anticancer therapy National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) Version 4.03 Grade less equal 1 . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) ≤ 2 . Adult patient age 18 year old . Life expectancy least 3 month . Key Current participation another therapeutic clinical trial . Prior treatment entrectinib . History prolong QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 millisecond ) . History additional risk factor torsade de pointes ( e.g. , family history long QT syndrome ) . Known active infection ( bacterial , fungal , viral include HIV positivity ) . Gastrointestinal disease ( e.g. , Crohn 's disease , ulcerative colitis , short gut syndrome ) malabsorption syndrome would impact drug absorption . Known interstitial lung disease , interstitial fibrosis , history tyrosine kinase inhibitorinduced pneumonitis . Peripheral neuropathy ≥ Grade 2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>